Business Standard

Tuesday, December 24, 2024 | 05:40 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Covid-19: Serum's Covovax gets the nod as a mix-and-match booster shot

Experts say no current vaccine protects against sub-lineages of Omicron

vaccine
Premium

Sohini Das Mumbai
As India's Covid-19 daily case count dips below the 100-mark, approvals for vaccines to be used as a mix-and-match dosing third shot are coming through. After Bharat Biotech's nasal vaccine got the nod as a heterologous booster for the Covishield and Covaxin two-dose primary regimen, it's the turn of Serum Institute of India's Covovax.

The Drugs Controller General of India (DCGI) has approved the market authorisation for SII's Covovax – the Novavax vaccine made in India – as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin. In 2022, the DCGI approved Cobevax,

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in